Relmada Therapeutics (RLMD) Operating Expenses (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Operating Expenses data on file, last reported at $19.5 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 6.82% year-over-year to $19.5 million in Q1 2026; TTM through Mar 2026 was $60.3 million, a 23.73% decrease from a year earlier, with the FY2025 full-year figure at $59.1 million, down 29.55% from the prior year.
• Operating Expenses for Q1 2026 stood at $19.5 million, down from $20.3 million in the prior quarter.
• Over the last five years, Operating Expenses for RLMD reached as high as $45.5 million in Q2 2022 and fell as low as $10.2 million in Q2 2025.
• Historically, Operating Expenses has averaged $25.1 million across 5 years, with a median of $23.0 million in 2024.
• Across the five-year window, Operating Expenses jumped 71.99% in 2022 and slumped 55.12% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $38.7 million in 2022, then sank by 30.68% to $26.8 million in 2023, then fell by 28.9% to $19.1 million in 2024, then climbed by 6.59% to $20.3 million in 2025, then declined by 4.29% to $19.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $19.5 million in Q1 2026, $20.3 million in Q4 2025, and $10.3 million in Q3 2025.